Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SRL172

Known as: SRL 172 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Two studies were carried out to evaluate heat-killed Mycobacterium vaccae SRL172 as an immunotherapeutic agent for patients with… Expand
Is this relevant?
2008
2008
Immunotherapy with a heat-killed suspension of Mycobacterium vaccae (SRL172), given with chemotherapy, in a phase III trial… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND This open-label, randomised phase III study was designed to further investigate the clinical activity and safety of… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2003
2003
T-helper (Th)2 cytokines play a central role in asthma. Therefore, a double-blind randomised study was conducted to investigate… Expand
Is this relevant?
2003
2003
We conducted a randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 (IL-2) as treatment for… Expand
Is this relevant?
2002
2002
BACKGROUND Mortality rates of HIV-infected patients treated for tuberculosis remain high. This study aimed to assess the effect… Expand
Is this relevant?
2002
2002
BACKGROUND SRL172 is a suspension of heat killed Mycobacterium vaccae, that has been found to be a potent immunological adjuvant… Expand
Is this relevant?
2000
2000
Mycobacterial preparations have been used with limited success against cancer apart from superficial bladder cancer. Recently, a… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
1998
1998
OBJECTIVE To assess whether a new heat-killed Mycobacterium vaccae preparation (SRL172), which enhances cell-mediated immunity… Expand
Is this relevant?
1998
1998
OBJECTIVE To evaluate the potential of heat-killed Mycobacterium vaccae (SRL172) as a nonspecific immunostimulant and as an… Expand
Is this relevant?